Chronic lymphocytic leukaemia with 17p deletion: A retrospective analysis of prognostic factors and therapy results

British Journal of Haematology

Volumn 157, Issue 1, 2012, Pages 67-74

  Delgado, Julio ^a,b   Espinet, Blanca ^c   Oliveira, Ana C ^d   Abrisqueta, Pau ^e   de la Serna, Javier ^f   Collado, Rosa ^g   Loscertales, Javier ^h   Lopez, Montserrat ⁱ   Hernandez Rivas, Jose A ^j   Ferra, Christelle ^k   Ramirez, Angel ^l   Roncero, Josep M ^m   Lopez, Cristina ^a   Aventin, Anna ^b   Puiggros, Anna ^c   Abella, Eugenia ^c   Carbonell, Felix ^g   Costa, Dolors ^a   Carrio, Anna ^a   Gonzalez, Marcos ⁿ  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b Hospital Sant Pau   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d HOSPITAL DURAN I REYNALS   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^h HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^j HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^k HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^l HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^m HOSPITAL JOSEP TRUETA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

more..

Author keywords

17p ; Chronic lymphocytic leukaemia; TP53

Indexed keywords

ALEMTUZUMAB; BETA 2 MICROGLOBULIN; CD38 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GLUCOCORTICOID; IMMUNOGLOBULIN G; MITOXANTRONE; PREDNISONE; PROTEIN KINASE ZAP 70; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; EVENT FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SYMPTOM; TREATMENT RESPONSE; TRISOMY 12;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84858284750     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.09000.x     Document Type: Article

References (26)

1. Best, O.G., Gardiner, A.C., Davis, Z.A., Tracy, I., Ibbotson, R.E., Majid, A., Dyer, M.J.S. & Oscier, D.G. (2009) A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia, 23, 212-214.
2. Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M.J.S., Fbezares, R., Pettitt, A.R., Hamblin, T., Milligan, D.W., Child, J.A., Hamilton, M.S., Dearden, C.E., Smith, A.G., Bosanquet, A.G., Davis, Z., Brito-Babapulle, V., Else, M., Wade, R. & Hillmen, P. (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet, 370, 230-239.
3. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. & Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990-4997.
4. Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., Marce, S., Lopez-Guillermo, A., Campo, E. & Montserrat, E. (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. New England Journal of Medicine, 348, 1764-1775.
5. Delgado, J., Pratt, G., Phillips, N., Briones, J., Fegan, C., Nomdedeu, J., Pepper, C., Aventin, A., Ayats, R., Brunet, S., Martino, R., Valcarcel, D., Milligan, D. & Sierra, J. (2009) Beta(2)-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. British Journal of Haematology, 145, 801-805.
6. Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S., Volkmann, M., Galle, P.R., Poustka, A., Hunstein, W. & Lichter, P. (1995) P53 gene deletion predicts for poor survival and nonresponse to therapy with purine analogs in chronic B-Cell leukemias. Blood, 85, 1580-1589.
7. Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., Dohner, K., Bentz, M. & Lichter, P. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. New England Journal of Medicine, 343, 1910-1916.
8. Dreger, P., Corradini, P., Kimby, E., Michallet, M., Milligan, D., Schetelig, J., Wiktor-Jedrzejczak, W., Niederwieser, D., Hallek, M. & Montserrat, E. (2007) Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia, 21, 12-17.
9. Dreger, P., Dohner, H., Ritgen, M., Bottcher, S., Busch, R., Dietrich, S., Bunjes, D., Cohen, S., Schubert, J., Hegenbart, U., Beelen, D., Zeis, M., Stadler, M., Hasenkamp, J., Uharek, L., Scheid, C., Humpe, A., Zenz, T., Winkler, D., Hallek, M., Kneba, M., Schmitz, N. & Stilgenbauer, S. (2010) Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood, 116, 2438-2447.
10. Gonzalez, D., Martinez, P., Wade, R., Hockley, S., Oscier, D., Matutes, E., Dearden, C.E., Richards, S.M., Catovsky, D. & Morgan, G.J. (2011) Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 Trial. Journal of Clinical Oncology, 29, 2223-2229.
11. Grever, M.R., Lucas, D.M., Dewald, G.W., Arenberg, D.S., Reed, J.C., Kitada, S., Flinn, I.W., Tallman, M.S., Appelbaum, F.R., Larson, R.A., Paietta, E., Jelinek, D.F., Gribben, J.G. & Byrd, J.C. (2007) Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US intergroup phase III Trial E2997. Journal of Clinical Oncology, 25, 799-804.
12. Haferlach, C., Dicker, F., Weiss, T., Schnittger, S., Beck, C., Grote-Metke, A., Oruzio, D., Kern, W. & Haferlach, T. (2010) Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters. Genes Chromosomes & Cancer, 49, 851-859.
13. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grunhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J.F., Berrebi, A., Jager, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Buhler, A., Winkler, D., Zenz, T., Bottcher, S., Ritgen, M., Mendila, M., Kneba, M., Dohner, H. & Stilgenbauer, S. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376, 1164-1174.
14. Lozanski, G., Heerema, N.A., Flinn, I.W., Smith, L., Harbison, J., Webb, J., Moran, M., Lucas, M., Lin, T., Hackbarth, M.L., Proffitt, J.H., Lucas, D., Grever, M.R. & Byrd, J.C. (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood, 103, 3278-3281.
15. Müller-Hermelink, H.K., Montserrat, E., Catovsky, D., Campo, E., Harris, N.L. & Stein, H. (2008) Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed. by S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S. Pileri, H. Stein, J. Thiele & J.W. Vardiman), pp. 180-182. IARC, Lyon, France.
16. Oscier, D., Wade, R., Davis, Z., Morilla, A., Best, G., Richards, S., Else, M., Matutes, E. & Catovsky, D. (2010) Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica-the Hematology Journal, 95, 1705-1712.
17. Robak, T., Dmoszynska, A., Solal-Celigny, P., Warzocha, K., Loscertales, J., Catalano, J., Afanasiev, B.V., Larratt, L., Geisler, C.H., Montillo, M., Zyuzgin, I., Ganly, P.S., Dartigeas, C., Rosta, A., Maurer, J., Mendila, M., Saville, M.W., Valente, N., Wenger, M.K. & Moiseev, S.I. (2010) Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology, 28, 1756-1765.
18. Sant, M., Allemani, C., Tereanu, C., De Angelis, R., Capocaccia, R., Visser, O., Marcos-Gragera, R., Maynadie, M., Simonetti, A., Lutz, J.M. & Berrino, F. (2010) Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood, 116, 3724-3734.
19. Schetelig, J., van Biezen, A., Brand, R., Caballero, D., Martino, R., Itala, M., Garcia-Marco, J.A., Volin, L., Schmitz, N., Schwerdtfeger, R., Ganser, A., Onida, F., Mohr, B., Stilgenbauer, S., Bornhaeuser, M., de Witte, T. & Dreger, P. (2008) Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European group for blood and marrow transplantation analysis. Journal of Clinical Oncology, 26, 5094-5100.
20. Shanafelt, T.D., Witzig, T.E., Fink, S.R., Jenkins, R.B., Paternoster, S.F., Smoley, S.A., Stockero, K.J., Nast, D.M., Flynn, H.C., Tschumper, R.C., Geyer, S., Zent, C.S., Call, T.G., Jelinek, D.F., Kay, N.E. & Dewald, G.W. (2006) Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. Journal of Clinical Oncology, 24, 4634-4641.
21. Shanafelt, T.D., Hanson, C., Dewald, G.W., Witzig, T.E., LaPlant, B., Abrahamzon, J., Jelinek, D.F. & Kay, N.E. (2008) Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. Journal of Clinical Oncology, 26, E5-E6.
22. Stilgenbauer, S., Sander, S., Bullinger, L., Benner, A., Leupolt, E., Winkler, D., Krober, A., Kienle, D., Lichter, P. & Dohner, H. (2007) Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica-the Hematology Journal, 92, 1242-1245.
23. Stilgenbauer, S., Zenz, T., Winkler, D., Buhler, A., Schlenk, R.F., Groner, S., Busch, R., Hensel, M., Duhrsen, U., Finke, J., Dreger, P., Jager, U., Lengfelder, E., Hohloch, K., Soling, U., Schlag, R., Kneba, M., Hallek, M. & Dohner, H. (2009) Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology, 27, 3994-4001.
24. Tam, C.S., Shanafelt, T.D., Wierda, W.G., Abruzzo, L.V., Van Dyke, D.L., O'Brien, S., Ferrajoli, A., Lerner, S.A., Lynn, A., Kay, N.E. & Keating, M.J. (2009) De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood, 114, 957-964.
25. Wierda, W.G., O'Brien, S., Wang, X.M., Faderl, S., Ferrajoli, A., Do, K.A., Garcia-Manero, G., Cortes, J., Thomas, D., Koller, C., Burger, J., Lerner, S., Kantarjian, H. & Keating, M. (2009) Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. Journal of Clinical Oncology, 27, 1637-1643.
26. Zenz, T., Eichhorst, B., Busch, R., Denzel, T., Habe, S., Winkler, D., Buhler, A., Edelmann, J., Bergmann, M., Hopfinger, G., Hensel, M., Hallek, M., Dohner, H. & Stilgenbauer, S. (2010) TP53 mutation and survival in chronic lymphocytic leukemia. Journal of Clinical Oncology, 28, 4473-4479.